More Arovella Therapeutics Limited news
Arovella Therapeutics LimitedASX: ALA

Investor Presentation March 2021

Mar 29, 2021 at 10:21 PM EDT · Issued by Arovella Therapeutics Limited

Filed with ASX · Mar 29, 2021 at 10:21 PM EDT

On 6ix: 6ix.com/news/investor-presentation-march-2021-1

Arovella Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Arovella Therapeutics Limited on 6ix

In the deck

  • Arovella Therapeutics — Investor Presentation (March 2021)24 slidesMar 30, 2021

Story so far

  • AGM FY20 PresentationNov 25, 2020
  • Investor Presentation November 2020Nov 17, 2020

Earlier from Arovella Therapeutics

  • Anagrelide Project UpdateFeb 25, 2021
  • Appendix 4D & Interim Financial Half Year Report FY2021Feb 25, 2021
  • Zelira Therapeutics Feasibility Study UpdateFeb 15, 2021
  • Company Update - Letter to ShareholdersDec 21, 2020
  • Prospectus - PlacementDec 15, 2020

Later from Arovella Therapeutics

  • SUDA Licenses a Novel iNKT Cell Therapy PlatformJun 18, 2021
  • Investor Presentation incorporating iNKT Cell PlatformJun 18, 2021
  • SUDA Placement Raises $3.65mJun 22, 2021
  • Disclosure Document Prospectus $3.65mJun 22, 2021
  • SUDA appoints new cell and gene therapy manufacturing expertAug 1, 2021
All Arovella Therapeutics news releases↗

Follow Arovella Therapeutics into a list and get an email when it puts out news.

Follow Arovella Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer